Nature of the Unidentified TeV Source HESS J1614-518, Revealed by Suzaku and XMM-Newton Observations

We report on new Suzaku and XMM-Newton results concerning HESS J1614-518, which is one of the brightest extended TeV gamma-ray sources and has two regions with intense gamma-ray emission. We newly observed the south and center regions of HESS J1614-518 with Suzaku, since the north region, including the position of the 1st brightest peak of the TeV gamma-ray emission, has already been observed. No X-ray counterpart was found at the position of the 2nd brightest peak of the TeV gamma-ray emission; we estimated the upper limit of the X-ray flux to be 1.6 \times 10^{-13} erg cm^{-2} s^{-1} in the 2-10 keV band. The soft X-ray source Suzaku J1614-5152, which was found at the edge of the field of view in a previous observation, was also detected at the middle of HESS J1614-518. Analyzing the XMM-Newton archival data, we revealed that Suzaku J1614-5152 consists of multiple point sources. The X-ray spectrum of the brightest point source, XMMU J161406.0-515225, can be described by a power-law model with a photon index of Gamma = 5.2^{+0.6}_{-0.5}, or a blackbody model with temperature kT = 0.38^{+0.04}_{-0.04} keV. In the blackbody model, the hydrogen-equivalent column density is almost the same as that of the hard extended X-ray emission, Suzaku J1614-5141, which was found at the 1st peak position. If true, XMMU J161406.0-515225 may be physically related to Suzaku J1614-5141 and HESS J1614-518.Comment: Accepted for publication in PASJ Vol.63 No.SP

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus

Introduction: Two studies were carried out to investigate the efficacy and safety of luseogliflozin added to existing oral antidiabetic drugs (OADs) in Japanese type 2 diabetic patients inadequately controlled with OAD monotherapy. Materials and Methods: In the trial involving add‐on to sulfonylureas (study 03‐1), patients were randomly assigned to receive luseogliflozin 2.5 mg or a placebo for a 24‐week double‐blind period, followed by a 28‐week open‐label period. In the open‐label trial involving add‐on to other OADs; that is, biguanides, dipeptidyl peptidase‐4 inhibitors, thiazolidinediones, glinides and α‐glucosidase inhibitors (study 03‐2), patients received luseogliflozin for 52 weeks. Results: In study 03‐1, luseogliflozin significantly decreased glycated hemoglobin at the end of the 24‐week double‐blind period compared with the placebo (–0.88%, P < 0.001), and glycated hemoglobin reduction from baseline at week 52 was –0.63%. In study 03‐2, luseogliflozin added to other OADs significantly decreased glycated hemoglobin from baseline at week 52 (–0.52 to –0.68%, P < 0.001 for all OADs). Bodyweight reduction was observed in all add‐on therapies, even with agents associated with weight gain, such as sulfonylureas and thiazolidinediones. Most adverse events were mild in severity. When added to a sulfonylurea, incidences of hypoglycemia during the double‐blind period were 8.7% and 4.2% for luseogliflozin and placebo, respectively, but no major hypoglycemic episodes occurred. The frequency and incidences of adverse events of special interest for sodium glucose cotransporter 2 inhibitors and adverse events associated with combined OADs were acceptable. Conclusions: Add‐on therapies of luseogliflozin to existing OADs improved glycemic control, reduced bodyweight and were well tolerated in Japanese type 2 diabetic patients. These trials were registered with the Japan Pharmaceutical Information Center (add on to sulfonylurea: JapicCTI‐111507; add on to other OADs: JapicCTI‐111508)

Supramolecular Singlet Fission of Pentacene Dimers within Polyaromatic Capsules

We herein report a new set of supramolecular nanotools for the generation and modulation of singlet fission (SF) of noncovalent/covalent pentacene dimers. Two molecules of a pentacene monomer with bulky substituents are facilely encapsulated by a polyaromatic capsule, composed of naphthalene-based bent amphiphiles, in water. The encapsulated noncovalent dimer converts to otherwise undetectable triplet pairs and an individual triplet in high quantum yields (179% and 53%, respectively) even under high dilution conditions. Within the capsule, a covalently linked pentacene dimer with bulky groups generates two triplet pair intermediates in parallel, which are hardly distinguished in bulk solution, in excellent total quantum yield (196%). The yield of the individual triplet is enhanced by 1.6 times upon encapsulation. For both types of pentacene dimers, the SF features can be readily tuned by changing the polyaromatic panels of the capsule (i.e., anthracene and phenanthrene).acceptedVersionPeer reviewe

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus

INTRODUCTION: Two studies were carried out to investigate the efficacy and safety of luseogliflozin added to existing oral antidiabetic drugs (OADs) in Japanese type 2 diabetic patients inadequately controlled with OAD monotherapy. MATERIALS AND METHODS: In the trial involving add-on to sulfonylureas (study 03-1), patients were randomly assigned to receive luseogliflozin 2.5 mg or a placebo for a 24-week double-blind period, followed by a 28-week open-label period. In the open-label trial involving add-on to other OADs; that is, biguanides, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, glinides and α-glucosidase inhibitors (study 03-2), patients received luseogliflozin for 52 weeks. RESULTS: In study 03-1, luseogliflozin significantly decreased glycated hemoglobin at the end of the 24-week double-blind period compared with the placebo (–0.88%, P < 0.001), and glycated hemoglobin reduction from baseline at week 52 was –0.63%. In study 03-2, luseogliflozin added to other OADs significantly decreased glycated hemoglobin from baseline at week 52 (–0.52 to –0.68%, P < 0.001 for all OADs). Bodyweight reduction was observed in all add-on therapies, even with agents associated with weight gain, such as sulfonylureas and thiazolidinediones. Most adverse events were mild in severity. When added to a sulfonylurea, incidences of hypoglycemia during the double-blind period were 8.7% and 4.2% for luseogliflozin and placebo, respectively, but no major hypoglycemic episodes occurred. The frequency and incidences of adverse events of special interest for sodium glucose cotransporter 2 inhibitors and adverse events associated with combined OADs were acceptable. CONCLUSIONS: Add-on therapies of luseogliflozin to existing OADs improved glycemic control, reduced bodyweight and were well tolerated in Japanese type 2 diabetic patients. These trials were registered with the Japan Pharmaceutical Information Center (add on to sulfonylurea: JapicCTI-111507; add on to other OADs: JapicCTI-111508)